Koo, To play it fair with our largest shareholder, Shenzhen Hepalink, I can see an "M&A right of first refusal option" play out between HL and a third-party equity BP partner. The third-party BP partner will provide the necessary funds for business operations and BOM2.

HL is too small to buy RVX at a market value price.  HL would need to purchase the first refusal option. They did that once before, it has expired.  There are some good points in these comments.  Option purchase would limit the fair market value as it did with transferring rights to Zenith.  Any option or buy out will be complicated with Zenith.

We will know more in a few weeks